Dr. Andy Rohrwasser joined MDF in November 2023. He brings with him a broad and diverse background in academic science, venture backed start-ups and public health. Andy’s domain expertise and passion are rare diseases, genetics and genomics, and newborn screening. Andy implemented gene agnostic, next-generation sequencing as a universal second tier newborn screening modality. Under his leadership, Utah was the first state in the US to implement population wide screening for Spinal Muscular Atrophy (SMA).

Andy serves as an adjunct associate professor in pediatric neurology at the University of Utah, where he also received his PhD in Human Genetics and an MBA. As the laboratory director for the Utah Public Health Laboratory he oversaw multiple operational units with diverse regulatory requirements, customer bases and stakeholders.

Andy was the principal investigator of multiple, multi-year research projects funded by HRSA, CMS, APHL, and CDC. He serves on multiple advisory committees for the CDC and APHL, and he has served as reviewer for NIH study sections, and multiple scientific journals as well as a member of the Utah IRB.